Back to mobile site

Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO)

December 10, 2025 6:38 AM EST Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $20.00 price target on Lexeo Therapeutics (NASDAQ: LXEO).The analyst comments "Lexeo ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login